Literature DB >> 21130412

Will newer tyrosine kinase inhibitors have an impact in AML?

Mark J Levis1.   

Abstract

FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21130412      PMCID： PMC3049331          DOI： 10.1016/j.beha.2010.09.008

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  33 in total

1.  Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.

Authors:  J Winkler; D Rech; S Kallert; J Rech; N Meidenbauer; W Roesler; A Mackensen
Journal:  Leuk Res       Date:  2010-06-02       Impact factor: 3.156

2.  Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

Authors:  D J Propper; A C McDonald; A Man; P Thavasu; F Balkwill; J P Braybrooke; F Caponigro; P Graf; C Dutreix; R Blackie; S B Kaye; T S Ganesan; D C Talbot; A L Harris; C Twelves
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

Review 4.  Bench to bedside targeting of FLT3 in acute leukemia.

Authors:  Keith W Pratz; Mark J Levis
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

5.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Authors:  Patrick P Zarrinkar; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Daniel Brigham; Barbara Belli; Mazen W Karaman; Keith W Pratz; Gabriel Pallares; Qi Chao; Kelly G Sprankle; Hitesh K Patel; Mark Levis; Robert C Armstrong; Joyce James; Shripad S Bhagwat
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

7.  Phase II trial of sorafenib in advanced thyroid cancer.

Authors:  Vandana Gupta-Abramson; Andrea B Troxel; Anoma Nellore; Kanchan Puttaswamy; Maryann Redlinger; Kathy Ransone; Susan J Mandel; Keith T Flaherty; Laurie A Loevner; Peter J O'Dwyer; Marcia S Brose
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

8.  KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

Authors:  Yukimasa Shiotsu; Hitoshi Kiyoi; Yuichi Ishikawa; Ryohei Tanizaki; Makiko Shimizu; Hiroshi Umehara; Kenichi Ishii; Yumiko Mori; Kazutaka Ozeki; Yosuke Minami; Akihiro Abe; Hiroshi Maeda; Tadakazu Akiyama; Yutaka Kanda; Yuko Sato; Shiro Akinaga; Tomoki Naoe
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

9.  A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.

Authors:  Keith W Pratz; Jorge Cortes; Gail J Roboz; Niranjan Rao; Omotayo Arowojolu; Adam Stine; Yukimasa Shiotsu; Aiko Shudo; Shiro Akinaga; Donald Small; Judith E Karp; Mark Levis
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

10.  A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Authors:  K W Pratz; E Cho; M J Levis; J E Karp; S D Gore; M McDevitt; A Stine; M Zhao; S D Baker; M A Carducci; J J Wright; M A Rudek; B D Smith
Journal:  Leukemia       Date:  2010-06-10       Impact factor: 11.528
View more
  6 in total

1.  Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Authors:  Weiguo Zhang; Chen Gao; Marina Konopleva; Ye Chen; Rodrigo O Jacamo; Gautam Borthakur; Jorge E Cortes; Farhad Ravandi; Abhijit Ramachandran; Michael Andreeff
Journal:  Clin Cancer Res       Date:  2014-03-11       Impact factor: 12.531

2.  FLT3/ITD AML and the law of unintended consequences.

Authors:  Mark Levis
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

3.  Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Authors:  A S Moore; A Faisal; D Gonzalez de Castro; V Bavetsias; C Sun; B Atrash; M Valenti; A de Haven Brandon; S Avery; D Mair; F Mirabella; J Swansbury; A D J Pearson; P Workman; J Blagg; F I Raynaud; S A Eccles; S Linardopoulos
Journal:  Leukemia       Date:  2012-02-22       Impact factor: 11.528

4.  Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.

Authors:  Xianzhou Song; Chengwei Zhang; Mingkun Zhao; Hui Chen; Xing Liu; Jianwei Chen; David M Lonard; Li Qin; Jianming Xu; Xiaosong Wang; Feng Li; Bert W O'Malley; Jin Wang
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

5.  Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.

Authors:  Vassilios Bavetsias; Simon Crumpler; Chongbo Sun; Sian Avery; Butrus Atrash; Amir Faisal; Andrew S Moore; Magda Kosmopoulou; Nathan Brown; Peter W Sheldrake; Katherine Bush; Alan Henley; Gary Box; Melanie Valenti; Alexis de Haven Brandon; Florence I Raynaud; Paul Workman; Suzanne A Eccles; Richard Bayliss; Spiros Linardopoulos; Julian Blagg
Journal:  J Med Chem       Date:  2012-10-08       Impact factor: 7.446

Review 6.  Aurora Kinase Inhibitors: Current Status and Outlook.

Authors:  Vassilios Bavetsias; Spiros Linardopoulos
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.